Docetaxel Trihydrate

Catalog No.S7787 Synonyms: RP56976 (NSC 628503) Trihydrate

Docetaxel Trihydrate Chemical Structure

Molecular Weight(MW): 861.93

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Size Price Stock Quantity  
USD 97 In stock
USD 197 In stock
USD 397 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (B) Viability of cells after exposure to 0, 10, or 10,000 nM docetaxel, assessed by calcein-AM staining (green, left panels) and ethidium homodimer-1 (red, middle panels). Right panels show merged images. Scale bars = 100 μm.

    Mol Pharm, 2014, 11(7):2040-50.. Docetaxel Trihydrate purchased from Selleck.

    Polymerized and soluble tubulin fractions from docetaxel untreated and treated FOXM1-siRNA and pcDNA3, 1-FOXM1 transfected cell lines were generated by centrifugation. Western blot was used to assay α-tubulin and β-tubulin ratios in polymerized and soluble fractions. (A) Relative percentages are shown above western blot.

    J Transl Med, 2013, 11:204.. Docetaxel Trihydrate purchased from Selleck.

  • Effect of siRNA-mediated knockdown for CDH1 in HCC4006ER cells. (A) Total cell lysates were harvested 72 hours after reverse-transfection of negative control siRNA (siNC) or validated siRNAs for CDH1 which encodes E-cadherin mixed with Lipofectamine RNAiMAX. (B-D) Tumor cells were reverse-transfected at the same time plating into 96-wells and then incubated for 24 hours. They were incubated with various concentrations of docetaxel, paclitaxel and vinorelbine for additional 72 hours. Percent growth relative to DMSO-treated controls was evaluated by Cell Counting Kit-8 assay.

    PLoS One,2015, 10(4):e0123901. Docetaxel Trihydrate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Targets
microtubules [1]
In vitro

Docetaxel is a cytotoxic agent, especially for proliferating cells, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by apoptosis of mitotically arrested cells or permanent mitotic block. Docetaxel suppresses microtubule dynamic instability as well as tread-milling, resulting in the failure of chromosomes to segregate to the daughter cells, which in turn triggers premature exit from mitosis rather than a block at this phase of the cell cycle. [2] Docetaxel inhibits the clonogenic survival of Human cancer cell Hs746T (stomach), AGS (stomach), HeLa (cervix), CaSki (cervix), BxPC3 (pancreas), Capan-1 (pancreas) with IC50 of 1 nM, 1 nM, 0.3 nM, 0.3 nM, 0.3 nM and 0.3 nM respectively. [4] Docetaxel inhibits endothelial cell migration that does not affects microtubule gross morphology or inhibit cell proliferation, although they does produce more subtle effects on microtubule dynamics. Docetaxel inhibits HUVEC migration with an observed IC50 of 1 pM. HUVEC chemotaxis stimulated by either of two angiogenic factors, thymidine phosphorylase or VEGF, is inhibited by Docetaxel with IC 50 of 10 pM and is ablated at 1 nM. [7] Docetaxel induces human monocytes, but not RAW 264.7 murine macrophages, Prostaglandin H Synthase-2m (PGHS-2) expression. [8]

In vivo Docetaxel (33 mg/kg/dose, given i.v. every 4 days for 3 injections) results in a tumor growth delay of 19.3 days in M2OL2 colon xenografts. Docetaxel also shows great antitumor activities in MX-1, SK-MEL-2, LX-1 and OVCAR-3 xenografts. Docetaxel inhibits the angiogenic response to fibroblast growth factor 2 with IC 50 of 5.4 mg/kg when injected twice weekly over a 14-day period, and angiogenesis is completely blocked in mice that receives 10 mg/kg Docetaxel. Docetaxel has selectivity for endothelial cell migration and/or microvessel formation because infiltration of inflammatory cells into the Matrigel plug is much less sensitive to inhibition by Docetaxel. [7]

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human gastric cancer cell lines MKN-28
  • Concentrations: 6 nM
  • Incubation Time: 3 days
  • Method: 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO2. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human colon carcinomas xenografts CX-1
  • Formulation: 50 mg/mL stock solution in ethanol by adding an equal volume of polysorbate 80 and diluting with 5% dextrose in water to the final volume
  • Dosages: 33 mg/kg
  • Administration: i.v. every 4 days for 3 injections
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (116.01 mM)
Ethanol 100 mg/mL (116.01 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 861.93
Formula

C43H53NO14.3H2O

CAS No. 148408-66-6
Storage powder
Synonyms RP56976 (NSC 628503) Trihydrate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02124902 Recruiting Triple Negative Breast Neoplasms Washington University School of Medicine July 7, 2014 Phase 2
NCT01683994 Recruiting Prostatic Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 6, 2012 Phase 1|Phase 2
NCT02649855 Recruiting Prostate Cancer|Prostate Neoplasms|Neoplasms, Prostatic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 4, 2016 Phase 2
NCT03041181 Recruiting Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Adenocarcinoma of the Lung|Lung Cancer Nasser Hanna, M.D.|Hoosier Cancer Research Network|Bristol-Myers Squibb January 27, 2017 Phase 2
NCT00251433 Active, not recruiting Neoplasms, Breast Novartis Pharmaceuticals|Novartis September 26, 2005 Phase 1
NCT01907529 Not yet recruiting Stage III Breast Cancer Hebei Medical University Fourth Hospital August 2018 Phase 2|Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Docetaxel Trihydrate | Docetaxel Trihydrate ic50 | Docetaxel Trihydrate price | Docetaxel Trihydrate cost | Docetaxel Trihydrate solubility dmso | Docetaxel Trihydrate purchase | Docetaxel Trihydrate manufacturer | Docetaxel Trihydrate research buy | Docetaxel Trihydrate order | Docetaxel Trihydrate mouse | Docetaxel Trihydrate chemical structure | Docetaxel Trihydrate mw | Docetaxel Trihydrate molecular weight | Docetaxel Trihydrate datasheet | Docetaxel Trihydrate supplier | Docetaxel Trihydrate in vitro | Docetaxel Trihydrate cell line | Docetaxel Trihydrate concentration | Docetaxel Trihydrate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID